Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.51 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HTR1B | P28222 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2935953 | 0.88 | CHRNB2 (0.57) | CHRNB2CHRNA4LTA4HKDM4EHRH3 | |
| SCHEMBL2933385 | 0.87 | CHRNB2 (0.56) | CHRNB2CHRNA4MEN1KMT2ALTA4H | |
| SCHEMBL3577214 | 0.84 | TSHR (0.55) | CHRNB2CHRNA4LTA4HRAB9AKDM4E | |
| SCHEMBL15884247 | 0.81 | L3MBTL1 (0.54) | CHRNB2CHRNA4MEN1KMT2AKDM4E | |
| SCHEMBL2934355 | 0.79 | L3MBTL1 (0.56) | CHRNB2CHRNA4MEN1KMT2AKDM4E | |
| SCHEMBL15206963 | 0.79 | GPR4 (0.47) | CHRNB2CHRNA4DRD3 | |
| SCHEMBL15884439 | 0.77 | HRH3 (0.54) | KDM4EALDH1A1HRH3 | |
| SCHEMBL4120225 | 0.76 | RAB9A (0.69) | MEN1KMT2AHTR1BLTA4HRAB9A | |
| SCHEMBL24568237 | 0.75 | CHRNB2 (0.64) | CHRNB2CHRNA4CXCR1 | |
| SCHEMBL19668758 | 0.75 | CHRNB2 (0.46) | CHRNB2CHRNA4RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240425482-A1 | PYRROLIDINE DERIVATIVES AS DDRS INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-12-26 | — | — | US | disclosed |
| EP-2229377-A1 | 5-ALKYL/ALKENYL-3-CYANOPYRIDINES AS KINASE INHIBITORS | Wyeth LLC (US) | 2010-09-22 | — | — | EP | disclosed |
| WO-2009076602-A1 | 5-ALKYL/ALKENYL-3-CYANOPYRIDINES AS KINASE INHIBITORS | WYETH (US) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240425482-A1 | PYRROLIDINE DERIVATIVES AS DDRS INHIBITORS | DDR1, DDR2, DDRGK1 | CHRNB2 3482/4885CHRNA4 4023/4885MEN1 3485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.